Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Redx Pharma Plc RNS Release

Result of AGM

RNS Number : 8678C
Redx Pharma plc
20 April 2017
 

20 April 2017

REDX PHARMA PLC

("Redx" or "the Company")

 

Result of Annual General Meeting

 

Redx, the drug discovery and development company, announces that all resolutions at the Group's Annual General Meeting, held today, were duly passed.

 

For further information, please contact:

 

Redx Pharma Plc


Neil Murray, Chief Executive

T: +44 1625 469 900 

Karl Hård, Head of Investor Relations &

Corporate Communications

T: +44 7491 651 406

 

Cantor Fitzgerald Europe (Nomad & Joint Broker)

 

T: +44 20 7894 7000

Phil Davies / Michael Reynolds


 

 

About Redx Pharma Plc

Company website: redxpharma.com

 

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGPGURGCUPMGUU



Redx Pharma Plc Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use